{"id":14670,"date":"2020-08-27T12:51:41","date_gmt":"2020-08-26T23:51:41","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=14670"},"modified":"2020-08-27T12:51:41","modified_gmt":"2020-08-26T23:51:41","slug":"burger-reviews-btk-inhibitors-and-beyond-in-frontline-cll","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=14670","title":{"rendered":"Burger Reviews BTK Inhibitors and Beyond in Frontline CLL"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″]<\/p>\n

Burger Reviews BTK Inhibitors and Beyond in Frontline CLL<\/h1>\n

[\/vc_custom_heading][vc_column_text]This article was originally published by Targeted Oncology<\/a><\/p>\n

During a virtual Case Based Peer Perspectives event, Jan A. Burger, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in Houston, TX, discussed testing and the treatment options for chronic lymphocytic leukemia (CLL), based on the a case of 71-year-old female patient.<\/p>\n

Targeted Oncology<\/em>TM<\/sup>: What testing would you order to confirm diagnosis if you saw this patient in the clinic?<\/strong><\/p>\n

BURGER<\/strong>: We need to establish the diagnosis by flow cytometry and then we would do, at a minimum, FISH cytogenetics and, ideally, the mutational status. Cytogenetics can change, but
\nmutational status usually doesn\u2019t change. If that\u2019s been established somewhere outside [of your clinic], then you don\u2019t have to repeat that test.<\/p>\n

It\u2019s important to repeat cytogenetics if you talk about the relapse setting. But here, we\u2019re treating in the frontline setting, and she was tested. She was found to be IGHV unmutated and [positive
\nfor] del(11q). That, traditionally, has been regarded as a higher-risk disease status because these patients respond OK to standard chemotherapy, but they have short remissions and survival times with FCR [fludarabine, cyclophosphamide, and rituximab (Rituxan)], BR [bendamustine plus rituximab], and those kinds of regimens compared with low-risk patients, such as those [who are positive for] deletion 13q and have IGHV mutated disease.<\/p>\n

In terms of these sequences, when you see a patient with lymphocytosis, you send for flow cytometry, and part of the flow cytometry panel can test for additional markers, CD38 and ZAP-70. We have it [at MD Anderson], but I\u2019m not sure if there are any\u00a0outside routine flow cytometry labs reporting CD38 positivity or negativity or ZAP-70. These markers used to be very popular 10
\nyears or so ago when IGHV-mutation status was not so commonly done and was more complicated to get. Nowadays, there\u2019s a shift with sending a sample directly for IGHV-mutation testing.<\/p>\n

To continue reading this article here on Targeted Oncology<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

During a virtual Case Based Peer Perspectives event, Jan A. Burger, MD, PhD, discussed testing and the treatment options for chronic lymphocytic leukemia, based on a case of 71-year-old female patient.<\/p>\n","protected":false},"author":1,"featured_media":14671,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17,23],"tags":[],"class_list":["post-14670","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured","category-research"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2020\/08\/Jan-A-Burger.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14670"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14670\/revisions"}],"predecessor-version":[{"id":14672,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14670\/revisions\/14672"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/14671"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}